Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis
Lorenzo Di Luozzo, Mariangela Salvato, Francesca Frizzera, Kiren Khalid, Margherita Zen, Andrea Doria, Roberta Ramonda, Alessandro Giollo · 2025
Read Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis by Lorenzo Di Luozzo, Mariangela Salvato, Francesca Frizzera, Kiren Khalid, Margherita Zen, Andrea Doria, Roberta Ramonda, Alessandro Giollo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717725.txt.
Description
Lorenzo Di Luozzo and co-authors compare the safety of two drug families after the first line fails in rheumatoid arthritis in a 2025 study. When anti-TNF drugs stop working, doctors choose between JAK inhibitors, small pills that block immune signaling, and other biologic drugs with different targets. Head-to-head safety data in exactly this switched population are thin.
The retrospective study followed three hundred five patients for up to two years, split between the two options. It counted adverse events per hundred patient-years and adjusted the comparison for disease activity and past biologic exposure. The groups started unevenly, with the biologic group sicker at baseline, which the analysis must handle honestly. Safety, more than power, often decides this prescription.
Catalog record
| CREATOR | Lorenzo Di Luozzo, Mariangela Salvato, Francesca Frizzera, Kiren Khalid, Margherita Zen, Andrea Doria, Roberta Ramonda, Alessandro Giollo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |